Lazard Asset Management LLC Raises Stock Holdings in argenx SE (NASDAQ:ARGX)

Lazard Asset Management LLC boosted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 1,086.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,637 shares of the company's stock after acquiring an additional 64,684 shares during the period. Lazard Asset Management LLC owned 0.12% of argenx worth $43,440,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. GeoWealth Management LLC grew its position in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in argenx during the fourth quarter valued at about $37,000. Global Retirement Partners LLC lifted its stake in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares in the last quarter. FIL Ltd acquired a new position in shares of argenx in the 4th quarter valued at about $38,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares during the period. Institutional investors own 60.32% of the company's stock.

argenx Trading Up 0.7%

ARGX stock traded up $3.88 during midday trading on Friday, hitting $565.63. The company had a trading volume of 433,461 shares, compared to its average volume of 324,080. argenx SE has a 52 week low of $356.38 and a 52 week high of $678.21. The stock's 50 day moving average price is $591.92 and its 200 day moving average price is $612.84. The stock has a market cap of $34.54 billion, a price-to-earnings ratio of -642.76 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Citigroup reissued an "outperform" rating on shares of argenx in a research report on Wednesday. Robert W. Baird raised argenx from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research report on Tuesday. Baird R W raised argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Finally, Guggenheim cut their price objective on argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, argenx presently has a consensus rating of "Buy" and a consensus target price of $698.11.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.